Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeanne M Link

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Molecular Imaging and Biology|October 31, 2013
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2014
Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer DiseaseAnand K Deo, Soo Borson, Jeanne M Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancerHannah M Linden, Svetlana A Stekhova, Jeanne M Link, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survivalAlexander M Spence, Mark Muzi, Kristin R Swanson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 28, 2020
<sup>18</sup>F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast CancerLanell M Peterson, Brenda F Kurland, Fengting Yan, et al.
Breast Cancer Research : BCR|August 24, 2021
<sup>18</sup>F-fluorodeoxyglucose (FDG) PET or <sup>18</sup>F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity studyPerrin E Romine, Lanell M Peterson, Brenda F Kurland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancerHannah M Linden, Brenda F Kurland, Lanell M Peterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
The progress and promise of molecular imaging probes in oncologic drug developmentGary J Kelloff, Kenneth A Krohn, Steven M Larson, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Molecular Imaging and Biology|October 31, 2013
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2014
Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer DiseaseAnand K Deo, Soo Borson, Jeanne M Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancerHannah M Linden, Svetlana A Stekhova, Jeanne M Link, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survivalAlexander M Spence, Mark Muzi, Kristin R Swanson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 28, 2020
<sup>18</sup>F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast CancerLanell M Peterson, Brenda F Kurland, Fengting Yan, et al.
Breast Cancer Research : BCR|August 24, 2021
<sup>18</sup>F-fluorodeoxyglucose (FDG) PET or <sup>18</sup>F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity studyPerrin E Romine, Lanell M Peterson, Brenda F Kurland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancerHannah M Linden, Brenda F Kurland, Lanell M Peterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
The progress and promise of molecular imaging probes in oncologic drug developmentGary J Kelloff, Kenneth A Krohn, Steven M Larson, et al.
Pageof 6